May 7, 2021– Americans are charged at least two to four times more for 20 major brand-name drugs, according to a new report to Congress. The Government Accountability Office (GAO) looked at the retail prices charged for brand-name, single-source drugs in the U.S. and compared them with those charged in Australia, Canada, and France. The researchers were able to adjust U.S. … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]
JAMA Study Shows 340B Can Help Restrain Drug Price Hikes
September 22, 2020— A recent Wall Street Journal opinion piece by a pharmaceutical industry consultant resurfaces claims that statutory discounts for safety-net hospitals, health centers, and clinics are forcing drug companies to hike their prices. Drug manufacturers are using this false notion as a pretext for urging program cutbacks in the guise of “reforms” and for refusing … [Read more...]
Drug Pricing Looms Large on Capitol Hill This Fall
September 9, 2019– Congress is back in town this week after the end of its August recess, and lawmakers are gearing up for a busy fall with a major focus on how to slow down ever-increasing drug prices. The cost of prescription drugs is on the minds of members from both parties in Congress as well as members of the Trump administration. Before they left town, two Senate … [Read more...]
340B May Curb High Drug Prices, New JAMA Study Finds
July 9, 2019– The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian Reynolds of the Pew Charitable Trusts evaluated the … [Read more...]
A Healthy Dose of Sunlight for Drug Companies
April 1, 2019— Today is a very good day for safety-net hospitals and the patients in need who rely on them. After nine long years of delay and preparation, the federal government today launched a new secure website. The site will provide hospitals, clinics, and health centers participating in the 340B drug pricing program with information on the maximum amount – or ceiling … [Read more...]
Death, Taxes…and Drug Price Increases
July 6, 2018—There’s new evidence that pharmaceutical manufacturers have not gotten the message that the Trump administration and the American public want an end to rising drug prices. Research documenting a host of drug price increases in June and July above the rate of inflation could complicate the Trump administration’s advocacy for its drug pricing blueprint, which … [Read more...]